Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Targeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Syngenta partners with Biotalys
Syngenta has announced to leverage Biotalys AGROBODY technology platform to expand its biocontrol pipeline.
Phialogics AG bags pre-seed financing
Phialogics AG has got a 600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.
Forbion raises 1.35bn across two funds
European life sciences venture capital company Forbion has raised two oversubscribed funds totalling 1.35 bn.
Ariceum Therapeutics extends Series A to 47.75m
German radiopharmaceuticals developer Ariceum Therapeutics has raised a further 22.75m extension of its 25m Series A financing announced in June 2022.
Genmab and argenx combine antibody know-how
Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.
Adaptyv Biosytems launches protein engineering foundry
Swiss Adaptyv Biosystems Sàrl has launched two fast-feedback tools that allow cheap, rapid and minaturised validation of AI-designed proteins.
Researchers activate chemotherapeutics by ultrasound
Ultrasound that switches cancer drug on could significantly reduce chemotherapy side effects, German researchers found in preclinical studies.
FAO presents food safety assessment on cell-based protein products
At the beginning of April, the FAO presented a report entitled "Food safety aspects of cell-based food" to establish safety standards for cell-based proteins.
Mosaic Therapeutics closes $28m series A financing
Wellcome Sanger Institute spin out Mosaic Therapeutics has closed a $28m series A funding led by Syncona Investment Management Ltd, and Cambridge Innovation Capital.